We have shown that combined inhibition of OGT and CDK9 is toxic to prostate cancer cells (Itkonen et al. 2020), and here we used a multiomics approach to explain the mechanistic basis for the combinatorial effects. The gene discussed is CDK9; the disease is prostate carcinoma.